Assessing the value of future research in low-dose computed tomography lung cancer screening in the United States
Our research group is among the few in the U.S. with expertise in VoI methods, and we recently completed a project applying VoI analysis to prioritize cancer genomics trials for the SWOG clinical trials cooperative group. Herein, we propose to apply VoI methods to assess the value of future studies related to low-dose computed tomography (LDCT) lung cancer screening. Specifically, we propose to augment an existing lung cancer screening Markov state-transition model with inputs from the National Lung Screening Trial (NLST) database, and calculate the expected value of a variety of randomized trial, observational, and patient preference elicitation study designs.
Partnership with the NLST is important because VoI is largely based on the degree of parameter uncertainty, and so access to patient-level outcomes that allow calculation of point estimates and 95% confidence intervals is critical to conducting a rigorous analysis. Furthermore, we plan to stratify analyses to assess the value of studies focused on NLST sub-groups defined by age, gender, and smoking status, so patient-level information will be necessary to facilitate these custom calculations.
Broad categories of research questions/designs we will evaluate include:
-Assessing the comparative effectiveness of new screening protocols/technologies (e.g. Lung-RADs)
-Evaluating the potential harms of cumulative radiation exposure from long-term annual LDCT screening
-Elucidating the frequency, types, and downstream impacts of LDCT incidental findings
-Preference elicitation studies to evaluate the health-related quality of life impacts of screening
This project is important because health care systems are making substantial investments in building lung cancer screening processes, personnel, and infrastructure. Additional research will be needed to ensure that these investments yield optimal returns in the forms of earlier cancer detection, decreased mortality, and increased health-related quality of life. The findings of the proposed study will provide systematic and quantitative evidence to inform future investments in this translational process.
Specific Aim 1: To expand an existing low-dose computed tomography lung cancer screening Markov state-transition model to calculate value of information using data from the National Lung Screening Trial.
Specific Aim 2: Using the expanded lung cancer screening model, assess the expected value of information for a range of plausible future research studies and designs related to low-dose computed tomography lung cancer screening.
Lotte Steuten, PhD, MSc, Fred Hutchinson Cancer Research Center
Scott Ramsey, MD, PhD, Fred Hutchinson Cancer Research Center
Sander Brinkhof, MSc, Fred Hutchinson Cancer Research Center
Bernardo Goulart, MD, MS, Fred Hutchinson Cancer Research Center
Richard Kim, MD, PhD, Fred Hutchinson Cancer Research Center
The Potential Clinical, Resource Use, And Fiscal Impacts of Lung-Rads To Inform Lung Cancer Screening In Medicare
J. Roth, S.D. Sullivan, S. Ramsey, B. Goulart
Val Health. 2016
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.
Roth JA, Sullivan SD, Goulart BH, Ravelo A, Sanderson JC, Ramsey SD
J Oncol Pract. 2015 May; Volume [Epub ahead of print]: Pages [Epub ahead of print] PUBMED